Interest of pharmacoepidemiology for the study of anticoagulants - 22/03/19

Doi : 10.1016/j.therap.2018.09.075

Haleh Bagheri ^⁎
Inserm 1027, service de pharmacologie médicale et clinique, faculté de médecine, centre Midi-Pyrénées de pharmacovigilance de pharmaco-épidémiologie et d’informations sur le médicament, université de Toulouse, centre hospitalier universitaire de Toulouse, 31000 Toulouse, France

^⁎Service de pharmacologie médicale et clinique, faculté de médecine, 37, allées Jules Guesde, 31000 Toulouse, France.Service de pharmacologie médicale et clinique, faculté de médecine37, allées Jules GuesdeToulouse31000France

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	4
Iconographies	0
Vidéos	0
Autres	0

Summary

Anticoagulants are essential for the treatment of cardiovascular illnesses. With the ageing population in the West countries, and the consequent increase in the frequency of thrombogenic heart diseases oral anticoagulants represent a not insignificant portion of drug consumption. Over the past few years, direct oral anticoagulants (DOACs) have been marketed because they are easier to use than vitamine K antagonists (VKAs). The introduction of these drugs has raised two main issues: (1) progress of the switch from VKAs to DOACs; (2) the comparison of adverse drug reactions (primarily hemorrhagic) on DOACs compared to indirect oral anticoagulants (IOAs). This article is confined to discussing oral anticoagulants, focusing on the two issues outlined above, and the potential answers that may be found in pharmacoepidemiology studies.

Le texte complet de cet article est disponible en PDF.

Keywords : Direct oral anticoagulant, Vitamin K antagonist, Pharmacoepidemiology